Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans.
Experimental studies have demonstrated that the GABAergic system modulates acetylcholine release and, through GABA(A) receptors, tonically inhibits cholinergic activity. Little is known about the effects of GABA on the cholinergic activity in the human central nervous system. In vivo evaluation of some cholinergic circuits of the human brain has recently been introduced using a transcranial magnetic stimulation (TMS) protocol based on coupling peripheral nerve stimulation with TMS of the motor cortex. Peripheral nerve inputs have an inhibitory effect on motor cortex excitability at short intervals (short latency afferent inhibition, SAI). We investigated whether GABA(A) activity enhancement by lorazepam modifies SAI. We also evaluated the effects produced by lorazepam on a different TMS protocol of cortical inhibition, the short interval intracortical inhibition (SICI), which is believed to be directly related to GABA(A) activity. In 10 healthy volunteers, the effects of lorazepam were compared with those produced by quetiapine, a psychotropic drug with sedative effects with no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors, and with those of a placebo using a randomized double-blind study design. Administration of lorazepam produced a significant increase in SICI (F(3,9) = 3.19, P = 0.039). In contrast to SICI, SAI was significantly reduced by lorazepam (F(3,9) = 9.39, P = 0.0002). Our findings demonstrate that GABA(A) activity enhancement determines a suppression of SAI and an increase of SICI.
Di Lazzaro
V
V
Istituto di Neurologia, Università Cattolica, L.go A. Gemelli 8, 00168 Rome, Italy. vdilazzaro@rm.unicatt.it
Oliviero
A
A
Saturno
E
E
Dileone
M
M
Pilato
F
F
Nardone
R
R
Ranieri
F
F
Musumeci
G
G
Fiorilla
T
T
Tonali
P
P
D000328:Adult; D000704:Analysis of Variance; D004311:Double-Blind Method; D004574:Electromagnetic Fields; D019054:Evoked Potentials, Motor / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008140:Lorazepam / Q000494:pharmacology*; D009044:Motor Cortex / Q000187:drug effects* / Q000502:physiology; D009433:Neural Inhibition / Q000187:drug effects* / Q000502:physiology; D009475:Neurons, Afferent / Q000187:drug effects* / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors
D008140:Lorazepam
J Physiol. 2000 Mar 1;523 Pt 2:503-13
10699092
J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1064-9
16024879
Eur J Neurosci. 2000 Jun;12(6):1941-8
10886335
Exp Brain Res. 2000 Dec;135(4):455-61
11156309
J Physiol. 2001 Jan 15;530(Pt 2):307-17
11208978
Neurology. 2002 Aug 13;59(3):392-7
12177373
Brain Res. 2002 Nov 22;956(1):81-5
12426049
J Physiol. 2002 Nov 15;545(Pt 1):153-67
12433957
Eur J Neurosci. 2003 Jan;17(2):249-59
12542661
Exp Clin Psychopharmacol. 2003 Feb;11(1):56-72
12622344
Neuroreport. 2003 Apr 15;14(5):773-6
12692481
Brain. 2003 Aug;126(Pt 8):1883-94
12805105
Clin Neurophysiol. 2003 Oct;114(10):1834-40
14499745
Psychopharmacology (Berl). 2003 Nov;170(3):255-62
12904966
Exp Brain Res. 2004 Jan;154(1):1-10
14579004
Clin Neurophysiol. 2004 Feb;115(2):255-66
14744565
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):555-9
15026495
Brain. 2004 Apr;127(Pt 4):E8; author reply E9
15044312
J Neurophysiol. 2004 Jul;92(1):66-72
14724259
Clin Neurophysiol. 2004 Aug;115(8):1717-29
15261850
Proc Natl Acad Sci U S A. 1985 Sep;82(18):6344-8
3862134
J Comp Neurol. 1986 Aug 15;250(3):282-95
3528237
J Physiol. 1986 Jun;375:169-94
2879035
Synapse. 1991 Feb;7(2):151-68
1672782
Trends Neurosci. 1993 Jun;16(6):218-22
7688162
J Physiol. 1993 Nov;471:501-19
8120818
Exp Brain Res. 1996 Apr;109(1):127-35
8740215
Ann Neurol. 1996 Sep;40(3):367-78
8797526
Electroencephalogr Clin Neurophysiol. 1997 Dec;105(6):430-7
9448644
Neuroscience. 1998 Oct;86(3):937-47
9692729
Science. 1998 Aug 14;281(5379):985-8
9703513
Electroencephalogr Clin Neurophysiol. 1998 Oct;109(5):426-35
9851300
Clin Neurophysiol. 2000 May;111(5):794-9
10802448